Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus: A real-world experience

doi:10.4239/wjd.v15.i3.463

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1142)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-4) series.

Item

Count

PDF

WORD

HTML

615

Figures (1-5)

Tables (1-4)

Sum=787

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

106

Download

Sum=196

Publishing Process of This Article

Item

Count

Browse

Download

Sum=78

Mar 15, 2024 (publication date) through Apr 28, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Diabetes. Mar 15, 2024; 15(3): 463-474
Published online Mar 15, 2024. doi: 10.4239/wjd.v15.i3.463

Table 1 Baseline clinical and biochemical characteristics of 467 type 2 diabetes mellitus patients treated with sodium glucose cotransporter 2 inhibitors.

Baseline features	n (%) or median (IQR)
Female gender	173 (37.04%)
Age (yr)	64 (14.8)
Ethnicity
British white	338 (72.37%)
Diabetes duration (yr)	16 (9)
Diabetes duration ≥ 10 yr	335 (71.73%)
Years of treatment with SGLT2i	3.6 (2.1)
Body weight (kg)	99 (29)
BMI (kg/m²)	34 (7.58)
BP (mmHg)
Systolic	144 (21)
Diastolic	82 (16)
HbA1c (mmol/mol)	78 (25.5)
Serum creatinine (μmol/L)	74 (21)
eGFR (mL/min/m²)	88.5 (17)
Urine ACR	2.1 (3.95)
GGT	38 (0)
Concomitant medications
Basal-bolus (novorapid + long-acting insulin)	32 (18.7)
Mixed insulin (novomix-30 insulin)	53 (26.4)
Long-acting insulin (lemevir, toujeo, lantus, tresiba, absalgar)	83 (38.1)
Metformin	377 (83.9)
Sulfonylurea (glimepride/glyburide/glipizide)	199 (44.7)
DPP4 inhibitors (sitagliptin, saxagliptin, linagliptin, or alogliptin)	130 (29.1)
Pioglitazone	22 (5)
GLP1 inhibitor (dulaglutide, exanatide, semaglutide, liraglutide)	94 (20.9)

SGLT2i: Sodium glucose cotransporter-2 inhibitor; IQR: Interquartile range; BMI: Body mass index; BP: Blood pressure; HbA1c: Glycated hemoglobin; eGFR: Estimated glomerular filtration rate; ACR: Albumin creatinine ratio; GGT: Gamma glutamyl transpeptidase; DPP4: Dipeptidyl-peptidase 4; GLP1: Glucagon like peptide 1.

Table 2 Follow-up metabolic/clinical/lab parameters for dapagliflozin

Clinical/lab/parameter	Baseline, median (IQR; n)	6 months F/U, median (IQR; n)	12 months, median (IQR; n)	Latest, median (IQR; n)	P value (baseline vs latest)
HbA1c	78 (25.3; 227)	68 (25; 204)^a	66.5 (22.8; 190)^b	69 (24; 191)	< 0.001
Weight	101 (29.5; 198)	95.4 (28.2; 150)^a	95.9 (29.2; 144)^a	92.2 (25.6; 93)	< 0.001
BMI	33.7 (6.6; 81)	-	-	33.9 (6.38; 44)	0.002
Systolic BP	145 (21.3; 185)	-	142 (23; 159)	142 (23.3; 112)	0.080
Diastolic BP	84 (14; 185)	-	80 (14; 159)^b	80 (19.3; 112)	< 0.001
Albuminuria (> 3 mmol/mg)	5.2 (17.4; 39)	3 (14.9; 24)^a	2.1 (6.38; 18)^a	4.4 (11.9; 30)	0.063

^aP < 0.05.

^bP < 0.01.

BMI: Body mass index; BP: Blood pressure; HbA1c: Glycated hemoglobin; IQR: Interquartile range.

Table 3 Follow-up metabolic/clinical/lab parameters for canagliflozin

Clinical/lab/parameter	Baseline, median (IQR; n)	6 months F/U, median (IQR; n)	12 months, median (IQR; n)	Latest, median (IQR; n)	P value (baseline vs latest)
HbA1c	80 (25.5; 160)	67.5 (20; 132)^b	67 (16.3; 128)^b	66 (28; 135)	< 0.001
Weight	100 (28.3; 125)	97.6 (27.5; 91)^a	98.3 (30.4; 74)	95.3 (27.5; 58)	< 0.001
BMI	35.1 (8.1; 73)	-	-	32.5 (9.38; 50)	< 0.001
Systolic BP	145 (18; 121)	-	145 (21.3; 84)	138 (22.8; 64)	0.041
Diastolic BP	84 (18; 121)	-	80.5 (11.2; 84)^a	79.5 (19; 64)	0.013
Albuminuria (> 3 mmol/mg)	14.1 (42.6; 40)	17.1 (30.4; 12)	7.3 (12.3; 21)^a	8.9 (23.7; 28)	0.043

^aP < 0.05.

^bP < 0.01.

BMI: Body mass index; BP: Blood pressure; HbA1c: Glycated hemoglobin; IQR: Interquartile range.

Table 4 Follow-up metabolic/clinical/lab parameters for empagliflozin

Clinical/lab/parameter	Baseline, median (IQR; n)	6 months F/U, median (IQR; n)	12 months, median (IQR; n)	Latest, median (IQR; n)	P value (baseline vs latest)
HbA1c	75 (23.5; 80)	64.5 (25; 64)^b	67 (22.5; 59)^a	66.5 (25.8; 66)	0.002
Weight	92 (27.5; 57)	86 (22.8; 29)^a	82.8 (20.9; 20)^b	89.7 (27.5; 20)	0.207
BMI	33.7 (9.92; 24)	-	-	32.4 (5.57; 6)	0.10
Systolic BP	136 (24.3; 52)	-	137 (26; 23)	130 (25.3; 32)	0.096
Diastolic BP	74 (14.5; 52)	-	74 (16; 23)	75.5 (12.5; 32)	0.187
Albuminuria (> 3 mmol/mg)	6.4 (15; 19)	6.2 (11.8; 7)	3.2 (2.98; 6)	5.9 (2.35; 11)	0.79

^aP < 0.05.

^bP < 0.01.

BMI: Body mass index; BP: Blood pressure; HbA1c: Glycated hemoglobin; IQR: Interquartile range.

Citation: Islam L, Jose D, Alkhalifah M, Blaibel D, Chandrabalan V, Pappachan JM. Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus: A real-world experience. World J Diabetes 2024; 15(3): 463-474
URL: https://www.wjgnet.com/1948-9358/full/v15/i3/463.htm
DOI: https://dx.doi.org/10.4239/wjd.v15.i3.463